Comparative evaluation of ChatGTP-4o and ChatGTP-3.5 in clinical rule-guided dose interventions in hospitalized patients with renal dysfunction

P.D. van der Linden¹, M. van Nuland¹


¹Department of Pharmacy, Tergooi Medical Centre, Hilversum, the Netherlands


Aim

To evaluate the effectiveness of ChatGPT-4o compared to ChatGTP-3.5 in providing clinical rule-guided dose interventions for patients with renal impairment.

Background

- Clinical decision support systems (CDSS) play a crucial role in identifying medications that require dose modifications for patients with renal impairment.
- Large Language Models (LLM) like ChatGTP has potential for providing such dose recommendations.
- Performance of ChatGTP-3.5 was however subobtimal¹.
- Recently release of ChatGTP-4o





- Withouth patient specific information
- With patient specific information



ChatGTP-3.5

and

Expert panel:

Nephrologist

Hospital pharmacist



Advices

Determing accuracy of answers:

- 1. Dose advice by ChatGPT is correct and identical to the dose advice given by the expert panel,
- 2. Dose advice is correct but different from expert panel
- 3. Dose advice by ChatGPT is incorrect.

Results


• 172 CDSS alerts for 80 patients.

Performance ChatGTP-3.5

	Simple question	Complex question
"correct and identical"	19.9 %	16.7 %
"correct and different"	26.7 %	16.0 %
"incorrect responses"	53.4 %	67.3 %

Performance ChatGTP-4o

	Simple question	Complex question
"correct and identical"	41.3 %	39.0 %
"correct and different"	18.6 %	12.2 %
"incorrect responses"	40.1 %	48.8 %



Example of general and patient-specific presentation and responses for decreased renal function as presented to ChatGPT, including an example of both with metformin		
Format general question	A patient with an eGFR (CKD-EPI) of [eGFR] ml/min/1.73m2 is treated with [DRUG] [DOSE]mg [FREQUENCY]. What dose would a healthcare professional recommend?	
Example general question	A patient with an eGFR (CKD-EPI) of 45 ml/min/1.73m2 is treated with metformin 1000mg twice daily. What would a healthcare professional recommend regarding the metformin dose?	
Response general question	For a patient with an eGFR of 45 mL/min, I recommend reducing the metformin dose to 1000 mg per day to minimize the risk of lactic acidosis while ensuring safety in renal function.	
Format patient specific question	A [AGE]-year old [GENDER] with an eGFR (CKD-EPI) of [eGFR] ml/min is admitted to the [DEPARTMENT] with [REASON FOR ADMISSION]. She is treated with [DRUG] [DOSE]mg [FREQUENCY] for [DIAGNOSIS]. Her renal function prior to hospitalization was [eGFR] ml/min and the reason for decline in eGFR is [REASON FOR RENAL DYSFUNCTION]. [YES/NO] co-medication affecting renal function is being used [, BEING]. What dose would a healthcare professional recommend?	
Example patient specific question	A 88-year old female with an eGFR (CKD-EPI) of 45 ml/mi is admitted to the orthopedic surgery department with a broken hip at the surgery department. She is treated with metformin 1000 mg twice daily for type 2 diabetes mellitus. Her renal function prior to hospitalization was 70 ml/min and the reason for decline in eGFR is prerenal renal failure due to dehydration. No co-medication affecting renal function is being used. What would a healthcare professional recommend regarding the metformin dose?	
Response patient specific question	For an 88-year-old male with an eGFR of 45 mL/min, the recommended metformin dose is 500 mg twice a day (total 1000 mg/day) to minimize the risk of lactic acidosis while managing diabetes.	

Conclusion

The performance of ChatGPT-40 in clinical rule-guided dose interventions in hospitalized patients with renal dysfunction was much better than ChatGPT-3.5. However, it is not appropriate for automatic integration into our EHR to handle CDSS alerts related to renal dysfunction.





¹van Nuland M, Snoep JD, Egberts T, Erdogan A, Wassink R, van der Linden PD. Poor performance of ChatGPT in clinical rule-guided dose interventions in hospitalized patients with renal dysfunction. Eur J Clin Pharmacol. 2024 Aug;80(8):1133-1140. doi: 10.1007/s00228-024-03687-5.

Corresponding author: Paul van der Linden Email: pvanderlinden@tergooi.nl